Hypoglycemia in a Patient with Hypercortisolism and Adrenocortical Carcinoma: A Paradoxical Entity
Sushmita Khadka, MD, Shobha Mandal, MD, Vineela Kasireddy, MD, Subash Ghimire, MD, Tejaswini Maganti, MD, and Barbara Mols-Kowalczewski, MD
Adrenal cortical carcinoma is a rare and aggressive cancer with poor prognosis. Cases usually present with signs and symptoms of excessive hormone production. Hyperglycemia and Cushing syndrome are common, but tumor-associated hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-2 (termed An- derson’s syndrome) is uncommon. Given the rarity of adrenal cortical carcinoma, diagnosis and management of associated complications is challenging. In this study, we present a case of metastatic adrenal cortical carcinoma with a myriad of hormonal abnormalities. We will also briefly review literature regarding genetic association, pathophysiology, treatment options, and prognosis.
Keywords: adrenocortical carcinoma, tumor-associated hypoglycemia, hypercortisolism, paraneoplastic syndrome
Background
A DRENAL CORTICAL CARCINOMA (ACC) is a rare but ag- gressive cancer with an incidence of 0.72 cases per 1 million population per year. Median age of diagnosis is in fourth to fifth decade of life with female predilection.2,3 More than 50% of the patient have symptoms related to excess hormone production.4,5 The majority of ACCs secrete corti- sol, manifesting as hyperglycemia and Cushing’s syndrome; however, tumor-associated hypoglycemia (termed Anderson’s syndrome) due to paraneoplastic secretion of insulin-like- growth factor (IGF)-2 is a paradoxical rare entity reported.6 First described by Daughaday et al. in a patient with leio- myosarcoma with recurrent hypoglycemia, ACC now has been identified in various neuroendocrine tumors, adrenal, hepatocellular, gastrointestinal, and ovarian carcinoma.7,8 Resection of the tumor is the ultimate management for cor- rection of hypoglycemia and associated hormonal abnor- mality, but complete resection might not be feasible because of late presentation and progression of malignancy.
In this study, we discuss challenging case of metastatic adrenal carcinoma in young patient.
Case Presentation
Thirty-year-old male with no prior contact with health care presented with worsening left flank pain for 3 months. Ty- lenol and heating pads at home were not helping with the
pain. Blood pressure was 160/90 mmHg, and heart rate was 80 bpm. Abdominal tenderness in left upper quadrant without any rebound tenderness, 3+ of pitting pedal edema was present. There was no moon face, buffalo hump, or abdom- inal striae. Initial laboratories showed leukocytosis, transa- minitis, and hypokalemia (Table 1). Computed tomography (CT) scan of abdomen showed a 12 cm left suprarenal mass with multiple liver and lung metastasis (Fig. 1). Biopsy of a liver lesion showed adrenocortical carcinoma (Fig. 2), special stains were positive for calretinin, Melan A, and synapto- physin. Cytokeratin was negative (Table 2). His hospital course was complicated by refractory hypokalemia, hyper- tension, and symptomatic hypoglycemic episodes (blood glucose range 20-50 mg/dL). His serum cortisol level was high, failed to be suppressed by dexamethasone. Twenty-four hours urine catecholamines, metanephrines, and dehy- droepiandrosterone sulfate (DHEAS) were normal, whereas aldosterone, testosterone, thyroid stimulating hormone, free thyroxine, insulin, proinsulin, and C-peptide levels were suppressed. IGF-2 binding protein came back to be high confirming paraneoplastic hypoglycemia (Table 1). After consultation with oncology and endocrinology, he was ur- gently started on metyrapone, mitotane, and chemotherapy (cisplatin, doxorubicin, and etoposide) to attempt rapid de- bulking of tumor. He was also started on hydrocortisone and octreotide to help with hypoglycemia. He was requiring scheduled oral and IV dextrose. He received cornstarch sup- plements, which helped to stabilize his blood sugar. Although
| TABLE 1. INVESTIGATIONAL RESULTS | ||
| Investigational | ||
| results | ||
| Hemoglobin | 13 g/dL | 13.7-17.5 |
| White blood cells | 14.63 K/uL | 4.23-9.07 |
| Platelets | 200 K/uL | 163-337 |
| Sodium | 138 mmol/L | 134-145 |
| Potassium | 2.7 mmol/L | 3.5-5.1 |
| BUN | 87 mg/dL | 70-99 |
| Creatinine | 0.3 mg/dL | 0.8-1.5 |
| ALT | 147 U/L | 21-72 |
| AST | 77 U/L | 21-72 |
| Serum morning cortisol | 59.1 mcg/dL | 4.5-22.7 |
| ACTH | <5 pg/mL | 6-50 |
| Serum morning cortisol post-1 mg dexamethasone | 57.5 mcg/dL | 4.5-22.7 |
| 24 Hour urine cortisol | 5367.9 mcg | 4-50 |
| Serum aldosterone | <1 ng/dL | 3-16 |
| DHEAS | 621 mcg/dL | 85-6990 |
| 24 Hour urine metanephrine | 270 mcg | 115-695 |
| 24 Hour urine HIAA | 4.6 mg | <6 |
| Total testosterone | 27 ng/dL | 250-1100 |
| Insulin | <1 µIU/mL | <19.6 |
| Proinsulin | <4 pmol/L | 18.8 pmol/L |
| C-peptide | <0.1 ng/ml | 0.8-3.85 |
| IGF-2 | 423 ng/ml | 38-267 |
ACTH, adrenocorticotrophic hormone; ALT, alanine transami- nase; AST, aspartate transaminase; BUN, blood urea nitrogen; DHEAS, dehydroepiandrosterone sulfate; HIAA, 5 hydroxyindo- leacetic acid; IGF-2, insulin-like growth factor-2.
he required multiple antihypertensives, including Aldactone for hypertension initially, later his blood pressure dropped and required addition of fludrocortisone. Surgical approach was considered as inappropriate because of significant metastatic burden and clinical instability. With chemotherapy he had
-
absolute neutropenia and anemia, and required blood transfu- sion and granulocyte monocyte colony stimulating factor in- jection. His abdominal pain continued to worsen and his mitotane and metyrapone dose was increased to 1000 and 750 mg three times daily, respectively. Repeat CT scan of ab- domen showed unchanged adrenal mass and metastasis. Second cycle of chemotherapy was given. He developed low-grade fever and blood culture grew Enterobacter cloacae. He devel- oped pneumonia and went into hypoxic respiratory failure re- quiring intubation and mechanical ventilation. Urinary antigen for legionella was positive. He was on broad spectrum antibi- otics with moxifloxacin. After multidisciplinary team discussion with the family regarding the prognosis, comfort care measures were applied. Patient died on 62nd day of initial presentation.
Discussion
ACC are considered to have a significant genetic component with various tumor predisposition syndromes. Li-Fraumeni syndrome with mutation in Tp53 gene, Beckwith-Wiedemann syndrome with mutation in chromosome 11p15, Carney complex with mutation in gene PRKAR1A are known as- sociations. In addition mutation in DNA mismatch repair gene and mutation of beta catenin pathway is also docu- mented.9 Biochemical and clinical evidence of excess adre- nocortical hormone production is seen in half of the patients. 10 High cortisol levels can saturate 11B-hydroxysteroid de- hydrogenase (HSD11B2) system, activating mineralocor- ticoid receptor causing hypertension and hypokalemia with hypercortisolism as seen in our patient. Paraneoplastic syndromes such as hyperreninemic hyperaldosteronism, erythropoietin-associated polycythemia, and leukocytosis are well recognized, whereas hypoglycemia is rare. Hypogly- cemia in adrenocortical carcinoma is due to production of IGF-2. It has insulin-like activity activating insulin recep- tors and promoting glucose uptake. It further causes inhi- bition of glycogenolysis and gluconeogenesis causing low blood sugar 11,12
European Network for Study of Adrenal Tumor (ENSAT) is now widely adopted staging of ACC-stage 1 and 2 are confined to adrenal gland, stage 3 has locoregional extension, whereas stage 4 represents metastatic disease.13 In total, 25%-30% of patients have metastatic disease at the time of presentation.3 For every ACC patient, biochemical evalua- tion guided by clinical presentation is necessary. Dex- amethasone suppression test, midnight salivary cortisol, and 24-hour urine cortisol can diagnose and estimate hypercorti- solism.14 Measurement of plasma renin, aldosterone, and DHEAS should be done to screen for mineralocorticoid ac- tivity and hyperandrogenism. DHEAS is considered as the most discriminative marker for ACC when compared with benign tumors.15 Exclude pheochromocytoma by measuring metanephrine and normetanephrine in plasma or urine to pre- vent catecholamine surge during surgery.16 IGF-2 measure- ment will help to diagnose tumor-associated hypoglycemia.
Gold standard treatment of ACC is surgical removal of mass for nonmetastatic disease, but it has remained suboptimal ad- juvant therapy.17,18 Mitotane with adrenolytic activity and specific destruction of inner zones of adrenal cortex is the only United States Food and Drug Administration (FDA) and Eu- ropean medicine executive agency approved drug for treating ACC.19 Mitotane can be started as 1g twice a day and
A
B
E
C
D
increased by 0.5-1 g every week with target plasma concen- tration of 14-20 mg/L. Gastrointestinal, neurological, and endocrinological side effects have to be monitored and man- aged.3 Cytotoxic chemotherapy with combination of mitotane plus etoposide, doxorubicin, and cisplatin is proven to have a good response rate.2º Hormonal abnormalities due to both ACC and treatment of ACC can be challenging. In metastatic ACC where surgical removal of mass is not an option, man- agement of hypercortisolism can be difficult, but steroido- genesis inhibitor ketoconazole and metyrapone or direct glucocorticoid antagonist mifepristone can be used.3 Tumor- associated hypoglycemia can be treated with glucose supple- ment and glucagon. Glucocorticoid therapy, which stimulates gluconeogenesis and partially suppresses IGF-2, has the most consistent benefit for managing hypoglycemia. Somatostatin analogues can be used in resistant cases. Management with enteral or parenteral nutrition should go side by side.8,21
Over recent decades our knowledge regarding pathology of ACC has broadened, but it remains as a disease with poor prognosis. With various associated hormonal abnormality and limited available treatment options, management is complicated and challenging.
| Immunohistochemistry on tumor cells | |
| Calretinin | Positive |
| Prostate-specific antigen | Negative |
| Pancytokeratin | Negative |
| Cytokeratin 7 | Negative |
| Leukocyte common antigen | Negative |
| Arginase | Negative |
| P40 | Negative |
| CD56 | Negative |
| CDX2 | Negative |
| Alfa-fetoprotein | Negative |
| CD30 | Negative |
| PAX8 | Negative |
| Melan A | Positive |
| Chromogranin | Negative |
| Synaptophysin | Positive |
| Thyroid transcription factor 1 | Negative |
| Cytokeratin 20 | Negative |
| Ki67 | 70% |
| S100 | Negative |
Author Disclosure Statement
No competing financial interests exist.
Funding Information
No funding was received for the work.
References
1. Kebebew E, Reiff E, Duh Q-Y, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872-8.
2. Audenet F, Méjean A, Chartier-Kastler E, Rouprêt M. Adrenal tumours are more predominant in females re- gardless of their histological subtype: a review. World J Urol. 2013;31(5):1037-43.
3. Else T, Kim AC, Sabolch A, et al. Adrenocortical carci- noma. Endocr Rev. 2014;35(2):282-326.
4. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195-201.
5. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006; 91(6):2027-37.
6. Ishikura K, Takamura T, Takeshita Y, et al. Cushing’s syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma. BMJ Case Rep. 2010;2010:bcr07.2009.2100.
7. Daughaday WH, Emanuele MA, Brooks MH, et al. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319(22):1434-40.
8. Schovanek J, Cibickova L, Ctvrtlik F, et al. Hypoglycemia as a symptom of neoplastic disease, with a focus on insulin- like growth factors producing tumors. J Cancer. 2019; 10(26):6475-80.
9. Paragliola RM, Corsello A, Locantore P, et al. Medical approaches in adrenocortical carcinoma. Biomedicines. 2020;8(12):551.
10. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor out- come of cortisol-secreting tumors in a series of 202 consec- utive patients. J Clin Endocrinol Metab. 2006;91(7):2650-5.
11. Iglesias P, Díez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol. 2014;170(4):R147-57.
ADRENOCORTICAL CARCINOMA
12. Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798- 826.
13. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009; 115(2):243-50.
14. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5): 1526-40.
15. Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabo- lomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12): 3775-84.
16. Song G, Joe BN, Yeh BM, et al. Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. Int Braz J Urol. 2011;37(1):31-5.
17. Zografos GC, Driscoll DL, Karakousis CP, Huben RP. Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol. 1994;55(3):160-4.
18. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113(11):3130-6.
19. Schteingart DE, Doherty GM, Gauger PG, et al. Manage- ment of patients with adrenal cancer: recommendations of an International Consensus Conference. Endocr Relat Cancer. 2005;12(3):667-80.
20. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-97.
21. Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014;99(3):713-22.
Address correspondence to: Sushmita Khadka, MD Department of Internal Medicine Guthrie Robert Packer Hospital 1 Guthrie Square Sayre, PA 18840 USA
Email: tshushmita@gmail.com